Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 909

1.

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.

Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA.

J Am Coll Cardiol. 2018 Sep 4;72(10):1081-1090. doi: 10.1016/j.jacc.2018.06.050.

PMID:
30165978
2.

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.

Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators.

N Engl J Med. 2018 Aug 27. doi: 10.1056/NEJMoa1808848. [Epub ahead of print]

3.

Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.

Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N.

ESC Heart Fail. 2018 Aug 25. doi: 10.1002/ehf2.12312. [Epub ahead of print]

PMID:
30145817
4.

Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.

Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA.

Eur Heart J. 2018 Aug 22. doi: 10.1093/eurheartj/ehy421. [Epub ahead of print]

PMID:
30137304
5.

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure.

Linssen GCM, Jaarsma T, Hillege HL, Voors AA, van Veldhuisen DJ.

Neth Heart J. 2018 Oct;26(10):486-492. doi: 10.1007/s12471-018-1145-x.

PMID:
30088253
6.

Epicardial fat in heart failure patients with mid-range and preserved ejection fraction.

van Woerden G, Gorter TM, Westenbrink BD, Willems TP, van Veldhuisen DJ, Rienstra M.

Eur J Heart Fail. 2018 Aug 1. doi: 10.1002/ejhf.1283. [Epub ahead of print]

PMID:
30070041
7.

T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF.

Abraityte A, Aukrust P, Kou L, Anand IS, Young J, Mcmurray JJV, van Veldhuisen DJ, Gullestad L, Ueland T.

Clin Res Cardiol. 2018 Jul 26. doi: 10.1007/s00392-018-1331-2. [Epub ahead of print]

PMID:
30051179
8.

Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review.

Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG.

Thromb Res. 2018 Sep;169:123-127. doi: 10.1016/j.thromres.2018.07.022. Epub 2018 Jul 19.

PMID:
30036784
9.

OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction.

van der Pol A, Gil A, Tromp J, Silljé HHW, van Veldhuisen DJ, Voors AA, Hoendermis ES, Grote Beverborg N, Schouten EM, de Boer RA, Bischoff R, van der Meer P.

Cardiovasc Res. 2018 Jul 19. doi: 10.1093/cvr/cvy187. [Epub ahead of print]

PMID:
30032247
10.

Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.

Ferreira JP, Duarte K, McMurray JJV, Pitt B, van Veldhuisen DJ, Vincent J, Ahmad T, Tromp J, Rossignol P, Zannad F.

Circ Heart Fail. 2018 Jul;11(7):e004926. doi: 10.1161/CIRCHEARTFAILURE.118.004926.

PMID:
29997240
11.

Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.

Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV.

Circ Heart Fail. 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.

PMID:
29980595
12.

Author Correction: Causal Pathways from Blood Pressure to Larger QRS Amplitudes: a Mendelian Randomization Study.

Van Der Ende MY, Hendriks T, Van Veldhuisen DJ, Snieder H, Verweij N, Van Der Harst P.

Sci Rep. 2018 Jul 3;8(1):10290. doi: 10.1038/s41598-018-27848-6.

13.

Waist-to-hip ratio and mortality in heart failure.

Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Lang CC.

Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1244. [Epub ahead of print]

PMID:
29963737
14.

Genome-wide studies of heart failure and endophenotypes: lessons learned and future directions.

van der Ende MY, Said MA, van Veldhuisen DJ, Verweij N, van der Harst P.

Cardiovasc Res. 2018 Jul 15;114(9):1209-1225. doi: 10.1093/cvr/cvy083.

PMID:
29912321
15.

Heart failure with preserved ejection fraction: from mechanisms to therapies.

Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ.

Eur Heart J. 2018 Aug 7;39(30):2780-2792. doi: 10.1093/eurheartj/ehy301.

PMID:
29905796
16.

Atrial fibrillation is more troublesome in heart failure patients with preserved compared to those with reduced ejection fraction.

Rienstra M, van Veldhuisen DJ.

Int J Cardiol. 2018 Sep 1;266:155-156. doi: 10.1016/j.ijcard.2018.04.114. No abstract available.

PMID:
29887436
17.

Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.

Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, Bakker SJL, Heymans S, van Empel V, Schroen B, van der Harst P, van Veldhuisen DJ, de Boer RA.

Eur J Heart Fail. 2018 Aug;20(8):1205-1214. doi: 10.1002/ejhf.1209. Epub 2018 Jun 1.

PMID:
29855124
18.

Biological versus mechanical heart valve prosthesis during pregnancy in women with congenital heart disease.

Lameijer H, van Slooten YJ, Jongbloed MRM, Oudijk MA, Kampman MAM, van Dijk AP, Post MC, Mulder BJ, Sollie KM, van Veldhuisen DJ, Ebels T, van Melle JP, Pieper PG.

Int J Cardiol. 2018 Oct 1;268:106-112. doi: 10.1016/j.ijcard.2018.05.038. Epub 2018 May 23.

PMID:
29848449
19.

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.

Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen DJ, Sauer WH, White M, Wilton SB, Anand IS, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR.

Am Heart J. 2018 May;199:51-58. doi: 10.1016/j.ahj.2017.12.001. Epub 2017 Dec 6.

PMID:
29754666
20.

Value of digoxin in patients with heart failure: new pieces to the puzzle.

van Veldhuisen DJ, Rienstra M, van der Meer P.

Eur J Heart Fail. 2018 Jul;20(7):1146-1147. doi: 10.1002/ejhf.1200. Epub 2018 Apr 20. No abstract available.

PMID:
29675974
21.

Causal Pathways from Blood Pressure to Larger Qrs Amplitudes a Mendelian Randomization Study.

Van Der Ende MY, Hendriks T, Van Veldhuisen DJ, Snieder H, Verweij N, Van Der Harst P.

Sci Rep. 2018 Apr 11;8(1):5817. doi: 10.1038/s41598-018-24002-0. Erratum in: Sci Rep. 2018 Jul 3;8(1):10290.

22.

Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging.

Te Rijdt WP, Ten Sande JN, Gorter TM, van der Zwaag PA, van Rijsingen IA, Boekholdt SM, van Tintelen JP, van Haelst PL, Planken RN, de Boer RA, Suurmeijer AJH, van Veldhuisen DJ, Wilde AAM, Willems TP, van Dessel PFHM, van den Berg MP.

Eur Heart J Cardiovasc Imaging. 2018 Apr 6. doi: 10.1093/ehjci/jey047. [Epub ahead of print]

PMID:
29635323
23.

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.

Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV.

Eur J Heart Fail. 2018 May;20(5):853-872. doi: 10.1002/ejhf.1170. Epub 2018 Mar 8. Review.

24.

Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.

Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, Rodenburg RJ, van Veldhuisen DJ, de Boer RA, van der Meer P.

Eur J Heart Fail. 2018 May;20(5):910-919. doi: 10.1002/ejhf.1154. Epub 2018 Feb 27.

25.

The Failing Heart Stimulates Tumor Growth by Circulating Factors.

Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HHW, de Boer RA.

Circulation. 2018 Feb 19. pii: CIRCULATIONAHA.117.030816. doi: 10.1161/CIRCULATIONAHA.117.030816. [Epub ahead of print]

26.

Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.

Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brügemann J, Geelhoed B, Tieleman RG, Hillege HL, Tukkie R, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC; RACE 3 Investigators.

Eur Heart J. 2018 Aug 21;39(32):2987-2996. doi: 10.1093/eurheartj/ehx739.

PMID:
29401239
27.

Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.

Ouwerkerk W, Zwinderman AH, Ng LL, Demissei B, Hillege HL, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Ter Maaten JM, Lang CC, van der Harst P, Filippatos G, Dickstein K, Cleland JG, Anker SD, Voors AA.

J Am Coll Cardiol. 2018 Jan 30;71(4):386-398. doi: 10.1016/j.jacc.2017.11.041.

PMID:
29389354
28.

Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients.

Grote Beverborg N, Klip IT, Meijers WC, Voors AA, Vegter EL, van der Wal HH, Swinkels DW, van Pelt J, Mulder AB, Bulstra SK, Vellenga E, Mariani MA, de Boer RA, van Veldhuisen DJ, van der Meer P.

Circ Heart Fail. 2018 Feb;11(2):e004519. doi: 10.1161/CIRCHEARTFAILURE.117.004519.

PMID:
29382661
29.

N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure.

Tromp J, Richards AM, Tay WT, Teng TK, Yeo PSD, Sim D, Jaufeerally F, Leong G, Ong HY, Ling LH, van Veldhuisen DJ, Jaarsma T, Voors AA, van der Meer P, de Boer RA, Lam CSP.

ESC Heart Fail. 2018 Apr;5(2):279-287. doi: 10.1002/ehf2.12252. Epub 2018 Jan 30.

30.

Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations.

van der Meer P, Grote Beverborg N, Pfeffer MA, Olson K, Anand IS, Westenbrink BD, McMurray JJV, Swedberg K, Young JB, Solomon SD, van Veldhuisen DJ.

Circ Heart Fail. 2018 Feb;11(2):e004431. doi: 10.1161/CIRCHEARTFAILURE.117.004431.

PMID:
29367268
31.

Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.

Beusekamp JC, Tromp J, van der Wal HH, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Rossignol P, Zannad F, Voors AA, van der Meer P.

Eur J Heart Fail. 2018 May;20(5):923-930. doi: 10.1002/ejhf.1079. Epub 2018 Jan 12.

PMID:
29327797
32.

Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction.

Gorter TM, Streng KW, van Melle JP, Rienstra M, Dickinson MG, Lam CSP, Hummel YM, Voors AA, Hoendermis ES, van Veldhuisen DJ.

Am J Cardiol. 2018 Mar 1;121(5):621-627. doi: 10.1016/j.amjcard.2017.11.040. Epub 2017 Dec 11.

PMID:
29307460
33.

Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure.

Ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Navis G, Ng L, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, de Borst MH.

Int J Cardiol. 2018 Feb 15;253:84-90. doi: 10.1016/j.ijcard.2017.10.010.

34.

Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure.

Emmens JE, Jones DJL, Cao TH, Chan DCS, Romaine SPR, Quinn PA, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M, de Boer RA, Voors AA, Ng LL.

Eur J Heart Fail. 2018 Feb;20(2):260-267. doi: 10.1002/ejhf.1101. Epub 2017 Dec 18.

PMID:
29251807
35.

Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation.

Gorter TM, van Melle JP, Rienstra M, Borlaug BA, Hummel YM, van Gelder IC, Hoendermis ES, Voors AA, van Veldhuisen DJ, Lam CSP.

J Card Fail. 2018 Mar;24(3):177-185. doi: 10.1016/j.cardfail.2017.11.005. Epub 2017 Nov 29.

36.

Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide.

Klaassen SHC, Tromp J, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, van Veldhuisen DJ, Hazenberg BPC.

Am J Cardiol. 2018 Jan 1;121(1):107-112. doi: 10.1016/j.amjcard.2017.09.029. Epub 2017 Oct 14.

37.

Anemia in Heart Failure: Still Relevant?

Grote Beverborg N, van Veldhuisen DJ, van der Meer P.

JACC Heart Fail. 2018 Mar;6(3):201-208. doi: 10.1016/j.jchf.2017.08.023. Epub 2017 Nov 8. Review.

PMID:
29128254
38.

Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH.

van der Pol A, Gil A, Silljé HHW, Tromp J, Ovchinnikova ES, Vreeswijk-Baudoin I, Hoes M, Domian IJ, van de Sluis B, van Deursen JM, Voors AA, van Veldhuisen DJ, van Gilst WH, Berezikov E, van der Harst P, de Boer RA, Bischoff R, van der Meer P.

Sci Transl Med. 2017 Nov 8;9(415). pii: eaam8574. doi: 10.1126/scitranslmed.aam8574.

PMID:
29118264
39.

The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis.

Bayes-Genis A, Núñez J, Zannad F, Ferreira JP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Metra M, Lupón J, Voors AA.

J Am Coll Cardiol. 2017 Oct 24;70(17):2128-2136. doi: 10.1016/j.jacc.2017.08.057.

40.

Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.

Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS, Crespo-Leiro MG, Guazzi M, Harjola VP, Heymans S, Hill L, Lainscak M, Lam CSP, Lund LH, Lyon AR, Mebazaa A, Mueller C, Paulus WJ, Pieske B, Piepoli MF, Ruschitzka F, Rutten FH, Seferovic PM, Solomon SD, Shah SJ, Triposkiadis F, Wachter R, Tschöpe C, de Boer RA.

Eur J Heart Fail. 2018 Jan;20(1):16-37. doi: 10.1002/ejhf.1029. Epub 2017 Oct 16. Review.

PMID:
29044932
41.

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.

Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D; Beta-blockers in Heart Failure Collaborative Group.

Eur Heart J. 2018 Jan 1;39(1):26-35. doi: 10.1093/eurheartj/ehx564.

42.

Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction.

Kaye DM, Silvestry FE, Gustafsson F, Cleland JG, van Veldhuisen DJ, Ponikowski P, Komtebedde J, Nanayakkara S, Burkhoff D, Shah SJ.

Eur J Heart Fail. 2017 Dec;19(12):1690-1697. doi: 10.1002/ejhf.930. Epub 2017 Oct 11.

43.

Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements.

Hummel YM, Liu LCY, Lam CSP, Fonseca-Munoz DF, Damman K, Rienstra M, van der Meer P, Rosenkranz S, van Veldhuisen DJ, Voors AA, Hoendermis ES.

Eur J Heart Fail. 2017 Dec;19(12):1651-1660. doi: 10.1002/ejhf.957. Epub 2017 Oct 6.

PMID:
28984057
44.

Pregnancy in women with corrected aortic coarctation: Uteroplacental Doppler flow and pregnancy outcome.

Siegmund AS, Kampman MAM, Bilardo CM, Balci A, van Dijk APJ, Oudijk MA, Mulder BJM, Roos-Hesselink JW, Sieswerda GT, Koenen SV, Sollie-Szarynska KM, Ebels T, van Veldhuisen DJ, Pieper PG; ZAHARA investigators.

Int J Cardiol. 2017 Dec 15;249:145-150. doi: 10.1016/j.ijcard.2017.09.167. Epub 2017 Sep 22.

PMID:
28966042
45.

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.

Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP, Desai AS, Solomon SD, Pfeffer MA, Cheng S, Gullestad L, Aukrust P, Ueland T, Swedberg K, Young JB, Kattan MW, Sattar N, McMurray JJV.

Eur J Heart Fail. 2018 Feb;20(2):268-277. doi: 10.1002/ejhf.988. Epub 2017 Sep 27.

PMID:
28960777
46.

Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?

Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC, Milo O, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJV, Teerlink JR; VERITAS Investigators.

Eur J Heart Fail. 2018 Feb;20(2):317-322. doi: 10.1002/ejhf.889. Epub 2017 Sep 4.

47.

High-sensitivity C-reactive protein and long term reperfusion success of primary percutaneous intervention in ST-elevation myocardial infarction.

Groot HE, Karper JC, Lipsic E, van Veldhuisen DJ, van der Horst ICC, van der Harst P.

Int J Cardiol. 2017 Dec 1;248:51-56. doi: 10.1016/j.ijcard.2017.08.027. Epub 2017 Aug 10.

48.

Vitamin D supplementation in heart failure: case closed?

de Boer RA, Meems LMG, van Veldhuisen DJ.

Eur Heart J. 2017 Aug 1;38(29):2287-2289. doi: 10.1093/eurheartj/ehx341. No abstract available.

PMID:
28810714
49.

Coronary angiography in worsening heart failure: determinants, findings and prognostic implications.

Ferreira JP, Rossignol P, Demissei B, Sharma A, Girerd N, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Voors A, Zannad F.

Heart. 2018 Apr;104(7):606-613. doi: 10.1136/heartjnl-2017-311750. Epub 2017 Aug 10.

50.

Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT.

Hartman MHT, Prins JKB, Schurer RAJ, Lipsic E, Lexis CPH, van der Horst-Schrivers ANA, van Veldhuisen DJ, van der Horst ICC, van der Harst P.

Clin Res Cardiol. 2017 Dec;106(12):939-946. doi: 10.1007/s00392-017-1140-z. Epub 2017 Jul 28.

Supplemental Content

Loading ...
Support Center